General MedicationsSOLUTIONStandard
ENFLONSIA
CLESROVIMAB-CFOR
Standard Dose
105MG/0.7ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview ENFLONSIA is listed in Drugs@FDA under application 761432 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient CLESROVIMAB-CFOR Form and strength INJECTION;SOLUTION - 105MG/0.7ML Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2025-06-09 00:00:00.
Structured Monograph
Clinical summary
Approval overview ENFLONSIA is listed in Drugs@FDA under application 761432 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CLESROVIMAB-CFOR Form and strength INJECTION;SOLUTION - 105MG/0.7ML Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2025-06-09 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.